Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
This article was originally published in The Pink Sheet Daily
Bayer Healthcare Chairman Jorg Reinhard says at BIO China that companies like Bayer must move away from their "comfort zone" and forge partnerships with Chinese companies.
You may also be interested in...
SINGAPORE - Drug companies are tightening their belts for discovery and development while also scanning different sectors of the globe for innovation. Bayer Schering Pharma Head of Global Drug Discovery Andreas Busch sees outside partnerships, or "externalization," as a necessity, particularly for high-risk innovation, and Bayer is looking to Asia Pacific for many of its discovery partners
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.